



RECEIVED
APR 10 2001
TECH CENTER 1600/2900

111. 0575/60849/JFW/APE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul B. Fisher, et al.
Serial No.: 09/515,363 Examiner: E. Loeb
Filed : February 29, 2000 Art Unit: 1636
For : MELANOMA DIFFERENTIATION ASSOCIATED GENE-5
(Mda-5), PROMOTER AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
April 3, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

**COMMUNICATION IN
RESPONSE TO THE MARCH 6, 2001
COMMUNICATION REGARDING SEQUENCE LISTING AND DISCLOSURES**

This Communication is submitted in response to the March 6, 2001 Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures issued by the United States Patent and Trademark Office in connection with the above-identified application. A copy of the Notice is attached hereto as **Exhibit A**. A response to the March 6, 2001 Communication is due April 6, 2001. Accordingly, this Communication is being timely filed.

Sequence Listing

The Examiner stated that the Communication filed February 9, 2001 was not fully responsive to the Office communication mailed November 1, 2001 because the Statement of Compliance filed February 9, 2001, certifying that the content of the paper and computer readable copies are the same, was unsigned and thus invalid. The Examiner stated that a substitute Statement should be submitted and specifically refer to the C.R.F. and paper copies filed February 9, 2001.

Applicants: Paul F. Fisher, et al.
Serial Number: 09/E1E,363
Filed: February 29, 2000
Page 2

In response, applicants herewith submit as **Exhibit B**, a signed Statement of Compliance Under 37 C.F.R. §1.821(d) certifying that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e) which was filed on February 9, 2001 in connection with the subject application has the same information as the paper copy of the Sequence Listing submitted as Exhibit 2 in the February 9, 2001 Communication.

Applicants believe that in view of the substitute Statement of Compliance, signed and submitted herewith, applicants fully comply with the requirements of 37 C.F.R. §1.821 through §1.825. Accordingly, applicants request that the Examiner withdraw this objection.


Applicants additionally attach as **Exhibit C**, a paper copy of the Sequence Listing submitted as Exhibit 2 in the February 9, 2001 Communication.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone at the number provided below.

Applicants: Paul F. Fisher, et al.
Serial Number: 09/818,363
Filed: February 29, 2000
Page 3

No fee is deemed necessary in connection with the filing of this communication. However, if any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage to insure first class delivery. It is addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20531.



John P. White
Reg. No. 28,678

4/3/01
Late

Notice to Comply

Application No.

09/515,363

Examiner

Ernwen M. Loeb

Applicant(s)

FISHER ET AL.

Art Unit

1636

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Statement filed February 90, 2001 that content of paper and computer readable copies are the same was unsigned and thus invalid; substitute statement should refer specifically to the CRF and paper copies filed Feb. 9, 2001

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY